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OBJECTIVES We sought to examine contemporary utilization patterns and clinical outcomes in patients
with acute myocardial infarction (AMI) requiring intra-aortic balloon pump (IABP)
counterpulsation.
BACKGROUND Despite increasing experience with and broadened indications for intra-aortic counterpulsa-
tion, the current indications, associated complications, and clinical outcomes of IABP use in
AMI are unknown.
METHODS Between June 1996 and August 2001, data were prospectively collected from 22,663
consecutive patients treated with aortic counterpulsation at 250 medical centers worldwide;
5,495 of these patients had AMI.
RESULTS Placement of an IABP in AMI patients was most frequently indicated for cardiogenic shock
(27.3%), hemodynamic support during catheterization and/or angioplasty (27.2%) or prior to
high-risk surgery (11.2%), mechanical complications of AMI (11.7%), and refractory
post-myocardial infarction unstable angina (10.0%). Balloon insertions were successful in
97.7% of patients. Diagnostic catheterization was performed in 96% of patients, and 83%
underwent coronary revascularization before hospital discharge. The in-hospital mortality
rate was 20.0% (38.7% in patients with shock) and varied markedly by indication and use of
revascularization procedures. Major IABP complications occurred in only 2.7% of patients,
despite median use for three days, and early IABP discontinuation was required in only 2.1%
of patients.
CONCLUSIONS With contemporary advances in device technology, insertion technique, and operator
experience, IABP counterpulsation may be successfully employed for a wide variety of
conditions in the AMI setting, providing significant hemodynamic support with rare major
complications in a high-risk patient population. (J Am Coll Cardiol 2003;41:1940–5)
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Following its introduction, intra-aortic balloon pump
(IABP) counterpulsation was principally applied to stabilize
medical and surgical patients with hemodynamic collapse
and to increase myocardial oxygen supply as a last resort in
patients with incipient cardiac arrest (1,2). Although the
IABP is still widely used in patients with cardiogenic shock,
accumulating clinical experience and trial data have resulted
in significant expansion of the indications for aortic coun-
terpulsation in patients with acute myocardial infarction
(AMI) (3). Evidence may be cited supporting the use of the
IABP in AMI patients with ventricular septal rupture and
acute mitral insufficiency (4,5), post-infarct angina (6),
recalcitrant ventricular arrhythmias (7), and progressive
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heart failure despite medical therapy (8). In patients with
AMI, the IABP may improve cardiac performance and
hemodynamic measures while the ischemic myocardium
recovers (9), decrease the incidence of recurrent ischemia
(10,11) and infarct-related artery reocclusion after reperfu-
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sion therapy (12,13), improve survival when used in con-
junction with thrombolytic therapy compared with throm-
bolytic therapy alone (14,15), and enhance rescue
angioplasty for failed thrombolysis (16).
Despite the increasing experience with and broadened
indications for aortic counterpulsation, the current utiliza-
tion patterns, associated complications, and clinical out-
comes of patients with AMI in whom an IABP is required
are unknown. As previously reported, the Benchmark
Counterpulsation Outcomes Registry was developed to
examine the patient profiles, device indications, hemody-
namic measures, clinical outcomes, and complications asso-
ciated with IABP in a broad cross section of patients (17).
The present report summarizes contemporary usage pat-
terns and outcomes in patients with AMI requiring IABP
counterpulsation from this large global registry.
METHODS
The details of the ongoing Benchmark Counterpulsation
Outcomes Registry, the participating sites, study organiza-
tion, and methodology for data collection and analysis have
previously been described (17). In brief, the Benchmark
Registry collects detailed clinical and device level data in
consecutive patients receiving an IABP on an institutional
level and affords individual hospitals the ability to compare
and contrast outcomes and usage patterns to the database as
a whole. The current analysis includes all consecutive
patients with AMI in participating institutions in whom an
IABP was placed between June 1996 (or the time of
institution initiation into the registry) and August 2001.
Concomitant medications and adjunctive procedures were
left to the discretion of the treating physician.
End points, definitions, and statistical methods. The
four principal clinical end points were ischemia, bleeding,
IABP failure, and in-hospital mortality. Major limb isch-
emia was defined as a loss of pulse or sensation, or abnormal
limb temperature or pallor requiring surgical intervention.
Minor ischemia involved decreased arterial flow, as mani-
fested by a diminished pulse that resolved with balloon
removal, not otherwise resulting in impairment of organ
function. Severe bleeding was defined as requirement of
blood transfusion or surgical intervention, or association
with hemodynamic compromise. Minor hematoma and
oozing from a puncture site not requiring blood transfusion
or surgical intervention was defined as nonsevere bleeding.
Failure of the IABP was defined as poor augmentation,
inability to deploy, or any IABP leak suggested by blood
inside the catheter tubing, gas loss, or catheter alarm.
All-cause hospital mortality was recorded as mortality oc-
curring from any cause during IABP use or after IABP
removal. Mortality directly related to IABP was also tabu-
lated. A major IABP-related complication was defined as
major limb ischemia, severe bleeding, IABP leak, or mor-
tality directly attributed to IABP. Components of the
clinical diagnosis of AMI, as well as infarct location, were
not prespecified but defined on-site using standard, local
definitions. Cardiogenic shock, however, was prospectively
defined as systolic blood pressure 90 mm Hg for 1 h (or
necessitating intravenous pressors of IABP for support),
associated with signs of systemic hypoperfusion (cool,
clammy skin, urine output 30 ml/h, or decreased level of
consciousness) or a cardiac index 2.0 l/min/m2, secondary
to cardiac dysfunction and not responsive to volume replace-
ment alone.
Descriptive summaries included frequency and percent
distributions for the categorical variables, and the sample
mean value SD for continuous variables. The paired t test
was used to compare the effect of IABP placement on
hemodynamic measures. Stepwise logistic regression was
performed to determine the independent correlates of in-
hospital mortality, considering age, gender, diabetes melli-
tus, previous MI, previous coronary artery bypass graft
surgery (CABG), peripheral vascular disease, left main
coronary artery (LMCA) involvement, cardiogenic shock,
and performance of percutaneous or surgical revasculariza-
tion in the model. All variables that were significant by
univariate analysis (likelihood ratio chi-square test), with a p
value 0.10, were included in the multivariate model. All
analyses were performed using SAS statistical software,
version 8 (SAS Institute, Cary, North Carolina). The
registry was validated by three audits (two independent and
one internal), which demonstrated a high degree of accuracy
(95% accuracy for check-box items and 90% accuracy
for dates). The largest external audit was performed by
StatTrade Inc. (Morrisville, Pennsylvania), and involved
485 records (20.7%) entered in 1999.
RESULTS
Clinical features and indications. Between June 1996 and
August 2001, 22,663 patients received an IABP at 250
centers (185 U.S. centers and 65 centers outside the U.S.);
AMI was the principal diagnosis in 5,495 (24%). The mean
age of the AMI population was 65.0  12.3 years (range 20
to 100 years); 34% were women. Twenty-six percent of
patients had diabetes mellitus, 25% had previous MI, 8%
had previous CABG, and 9% had peripheral vascular
disease. Of patients undergoing cardiac catheterization, 59%
had triple-vessel disease and 16% had LMCA involvement.
The mean ejection fraction was 36.5  14.3%. As seen in
Table 1, approximately one-half of the patients with AMI
required an IABP for cardiogenic shock or hemodynamic
Abbreviations and Acronyms
AMI  acute myocardial infarction
CABG  coronary artery bypass grafting
IABP  intra-aortic balloon pump
LMCA  left main coronary artery
SHOCK  SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK?
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support during or after cardiac catheterization or percuta-
neous intervention, whereas a variety of alternative reasons
were present in the other half of patients.
Performance and complications of IABP. The IABP was
inserted percutaneously in 98% of patients and by femoral
artery cutdown in 2%. A 9.5F system was utilized in 65% of
patients and an 8F system in 35%. A sheath was employed
in 80% of patients, whereas in 20%, insertion was sheath-
less. Of the balloon insertions, 2.3% were unsuccessful due
to a balloon leak, poor balloon inflation, poor augmentation
or difficulties associated with balloon insertion. As shown in
Table 2, IABP placement resulted in significant reductions
in systolic and diastolic arterial pressures, with no impact on
heart rate. The mean duration of IABP in the overall
registry cohort was 3.2  2.2 days (median 3 days, range 1
to 42 days).
One or more complications of IABP therapy occurred in
8.1% of patients (Table 3), although major complications
(severe limb ischemia, severe bleeding, balloon leak, or
death directly due to IABP insertion or failure) occurred in
only 2.7% of cases. Considering the five most common
indications for aortic counterpulsation, the occurrence of
major IABP-related complications did not significantly vary
(cardiogenic shock in 2.9%, support for high-risk catheter-
ization and angioplasty in 2.7%, surgery in 2.6%, mechanical
complications of AMI in 2.2%, and refractory unstable
angina in 3.1%; p  0.57). Death was directly attributed to
the IABP in only three patients (0.05%).
Angiography and revascularization procedures. Angiog-
raphy was performed in 5,348 patients (97.3%) during the
index hospitalization, and 4,476 patients (81.5%) under-
went coronary revascularization procedures, split approxi-
mately equally between percutaneous intervention (41.5%)
and CABG (40.0%). An additional 192 patients (3.5%)
underwent additional surgical procedures without revascu-
larization. A detailed list of the percutaneous and surgical
procedures performed in patients with AMI receiving an
IABP appears in Table 4. The rates of major IABP-related
complications were similar among patients undergoing an-
gioplasty (2.8%), surgery (2.6%), or conservative manage-
ment with or without angiography (2.7%).
In-hospital mortality. The mean duration of hospitaliza-
tion was 11.5  9.9 days (range 1 to 96 days). In-hospital
death occurred in 1,098 (20%) of 5,495 patients with AMI
in whom an IABP was placed; 581 (53%) of the 1,098
deaths occurred with the IABP in situ, whereas the remain-
der occurred after the device had been removed. As seen in
Figure 1, in-hospital mortality ranged from 6.4% in patients
Table 3. Failure and Complications of the IABP (n  5,495)
Complications
Any access-site bleeding 4.3%
Severe access-site bleeding 1.4%
Any limb ischemia 2.3%
Major limb ischemia 0.5%
Amputation 0.1%
Transfusion 1.4%
Vascular surgery 0.7%
Infection 0.1%
Deep venous thrombosis 0.1%
Superficial vein thrombosis 0.1%
Stroke 0.1%
Bowel, renal, or spinal cord infarction 0.1%
IABP-related mortality 0.05%
IABP failure
Any 2.3%
IABP leak 0.8%
Poor inflation 0.6%
Difficult insertion 0.1%
Poor augmentation 1.1%
Premature IABP removal 2.1%
IABP replaced 0.5%
IABP  intra-aortic balloon pump.
Table 4. Percutaneous and Surgical Procedures in Patients With
Acute Myocardial Infarction Receiving an Intra-Aortic
Balloon Pump*
Percutaneous (n  2,282)
Balloon angioplasty 100%
Stent 79.5%
Atherectomy 2.3%
Laser 0.1%
Other 3.3%
Surgical (n  2,388)
Bypass graft surgery 92.0%
Minimally invasive bypass grafting 0.9%
Mitral valve repair or replacement 9.1%
Aortic valve replacement 2.0%
Ventricular assist device 1.5%
Ventricular septal defect repair 0.5%
Orthotopic cardiac transplantation 0.4%
Transmyocardial revascularization 0.3%
Other 3.1%
*More than one procedure per patient may have been performed.
Table 1. Principal Indications for Intra-Aortic Balloon Pump
Use in 5,495 Patients With AMI
Cardiogenic shock 27.3%
Support for high-risk catheterization and angioplasty 27.2%
Mechanical complications of AMI (VSD and PMR) 11.7%
Pre-operative support for high-risk cardiac surgery 11.2%
Refractory post-MI unstable angina 10.0%
Weaning from cardiopulmonary bypass 4.8%
Refractory left ventricular failure 4.5%
Refractory ventricular arrhythmias 1.3%
Intra-operative support during surgery 0.5%
Other or indication not recorded 1.5%
AMI  acute myocardial infarction; MI  myocardial infarction; PMR  papillary
muscle rupture; VSD  ventricular septal defect.
Table 2. Effect of IABP Placement on Hemodynamic Measures
Pre-IABP Post-IABP p Value
Systolic blood pressure (mm Hg) 109  28 108  25 0.001
Diastolic blood pressure (mm Hg) 65  17 62  17 0.001
Augmented diastolic blood
pressure (mm Hg)
— 122  29 —
Mean arterial pressure (mm Hg) 82  21 87  21 0.001
Heart rate (beats/min) 89  24 90  23 0.59
Data are presented as the mean value  SD.
IABP  intra-aortic balloon pump.
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in whom the IABP was placed for refractory unstable angina
to 38.7% in patients requiring aortic counterpulsation for
cardiogenic shock. In-hospital mortality in patients with an
IABP also varied considerably, based on the use of revas-
cularization procedures, ranging from 12.5% in patients
undergoing CABG to 53.7% in those managed conserva-
tively (Fig. 2). Independent predictors of mortality in
patients with AMI requiring IABP placement are shown in
Table 5.
DISCUSSION
The principal findings of this study are: 1) IABP counter-
pulsation is used in patients with AMI for a variety of
purposes that extend beyond traditional indications; 2)
severe IABP-related complications are infrequent in pa-
tients with AMI, even in those in cardiogenic shock; and 3)
in-hospital mortality rates in this high-risk population vary
considerably, based on IABP indication and use of revas-
cularization procedures.
Indications for IABP use in AMI. According to the 1999
Task Force on Practice Guidelines of the American Heart
Association and American College of Cardiology (18), class
I indications for IABP use in AMI include: 1) cardiogenic
shock as a stabilizing measure for angiography and prompt
revascularization; 2) acute mitral regurgitation or ventricular
septal defect complicating AMI as stabilizing therapy for
angiography and repair/revascularization; 3) recurrent, in-
tractable ventricular arrhythmias with hemodynamic insta-
Figure 1. In-hospital mortality of 5,495 patients with acute myocardial infarction (AMI) requiring intra-aortic balloon pump counterpulsation, stratified
by principal usage indication. PCI  percutaneous coronary intervention.
Figure 2. In-hospital mortality stratified by the performance of angiography and percutaneous or surgical coronary revascularization.
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bility; and 4) refractory post-myocardial infarction angina as
a bridge to angiography and revascularization. In the present
series, these four categories comprised only 50% of the
indications for IABP use in patients with AMI. Significant
numbers of patients also received an IABP prophylactically
before angiography, percutaneous intervention, or surgical
revascularization, prompted by the frequent presence in this
population of prognostically adverse features such as de-
pressed left ventricular function and significant LMCA or
triple-vessel disease. Although the utility of IABP counter-
pulsation has not been established in these settings by
randomized clinical trials, the data from this large series
provide insight into contemporary usage patterns of IABP
counterpulsation and associated outcomes for these clinical
situations.
Performance and complications of IABP counterpulsa-
tion. Placement of an IABP resulted in notable augmen-
tation of diastolic blood pressure and a significant though
small reduction in systolic blood pressure, with no change in
heart rate. These finding suggest that the major hemody-
namic and clinical benefits of IABP counterpulsation will be
realized in patients with systemic hypotension, with rela-
tively little reduction in afterload or myocardial oxygen
demand. A limitation of this study, however, is that right
heart catheterization was not routinely performed before
and after IABP insertion (and the data were not recorded),
thus potentially masking any possible benefit of preload
reduction lowering the pulmonary capillary wedge pressure.
A unique finding of this study is in regard to the analysis
of successful IABP placement: in only 2.2% of patients
could IABP counterpulsation not be established due to
balloon leak, poor inflation, poor augmentation, or insertion
difficulty. Moreover, despite earlier reports documenting
high rates of adverse events secondary to IABP usage
(3,19–21), major IABP-related complications in patients
with AMI in this large, contemporary series were relatively
infrequent (2.7%). As a result, only 2.1% of patients
required premature discontinuation of the device. These
findings represent real-world documentation that advances
such as percutaneous insertion, smaller catheter diameter,
and appropriate use of adjunctive pharmacology have con-
siderably reduced the incidence of serious vascular compli-
cations (19–27). Thus, it is reassuring that the hemody-
namic benefits of IABP may be realized in this high-risk
patient cohort with relatively low risk.
Use of revascularization procedures and mortality. The
in-hospital mortality of patients with AMI requiring an
IABP varied greatly with the principal usage indication and
performance of coronary revascularization. The value of an
early revascularization strategy after IABP placement in
patients with cardiogenic shock has recently been clearly
demonstrated (28,29) and appears to currently be the
predominant intent at most centers, as angiography was
performed in more than 97% of AMI patients in the
Benchmark Registry (with revascularization in nearly 82%).
The mortality of patients with AMI requiring IABP sup-
port was greatest in those in whom angiography and
revascularization were not performed, consistent with pre-
vious small, randomized trials that found no survival benefit
of IABP counterpulsation in patients with AMI managed
conservatively (30,31). Indeed, in the present series, the
performance of coronary revascularization was a powerful
independent predictor of survival by multivariate analysis.
Moreover, the 38.7% rate of in-hospital mortality in the
1,498 patients with cardiogenic shock in the current report
is similar to the 46.7% 30-day mortality rate in 152 patients
assigned to the invasive arm of the SHould we emergently
revascularize Occluded Coronaries for cardiogenic shocK?
(SHOCK) trial (28). In both studies, 80% of patients
were revascularized. Finally, given its size and broad geo-
graphic representation, the current registry may be used to
“benchmark” in-hospital mortality rates of patients with
AMI requiring IABP counterpulsation for conditions other
than shock. Indeed, comparative outcomes data are regu-
larly given to the individual sites participating in the
Benchmark Registry to facilitate quality-control implemen-
tation.
Study limitations. The present study is a large-scale,
voluntary prospective registry and, as such, has the limita-
tions inherent in all registries, including selection (report-
ing) bias for patient recruitment and a lack of documenta-
tion of all relevant variables related to outcome. Site-to-site
variations in personnel and resources allocated to the regis-
try cannot be excluded, nor can regional, local, and individ-
ual differences in patients and practice patterns. To the
extent possible, some of these concerns may be alleviated by
the prospective nature of the registry, the results of the
validation audits demonstrating high accuracy and compli-
ance, and the use of multivariate analysis to correct for
differences in patient characteristics. The Benchmark
Counterpulsation Outcomes Registry, representing the
largest contemporary experience with IABP usage, there-
fore, should be viewed as complementary to well-designed,
randomized, controlled clinical trials. However, no ade-
quately powered, controlled trial has ever been performed to
demonstrate whether IABP counterpulsation does indeed
improve clinical outcomes and/or reduce mortality in pa-
tients with AMI and shock undergoing reperfusion therapy
Table 5. Independent Correlates of In-Hospital Mortality by
Logistic Regression Analysis
Multivariate Odds
Ratio (95% CI)
p
Value
Cardiogenic shock 3.95 (3.41–4.58) 0.0001
Age 75 yrs 2.36 (2.02–2.77) 0.0001
Previous myocardial infarction 1.52 (1.29–1.79) 0.0001
Female gender 1.47 (1.26–1.71) 0.0001
Previous bypass surgery 1.42 (1.12–1.81) 0.004
Peripheral vascular disease 1.29 (1.03–1.63) 0.03
Diabetes mellitus 1.18 (1.00–1.39) 0.0497
Performance of percutaneous
or surgical revascularization
0.38 (0.33–0.45) 0.0001
CI  confidence interval.
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or in a subset of such patients. As the entry criteria for the
Benchmark Registry required IABP usage, data from this
study cannot be used to support such a conclusion. Fre-
quency and outcomes data are also not available for patients
in whom IABP usage might have been beneficial, but in
whom placement of the device was contraindicated because
of peripheral vascular disease, aortic insufficiency, or other
adverse conditions. Finally, as right heart catheterization
data were not routinely collected in this study, no statements
can be made regarding the efficacy of IABP to reduce
preload and afterload in the AMI setting, either in patients
with or without cardiogenic shock.
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